Caribou Biosciences (CRBU) Receivables (2020 - 2026)

Caribou Biosciences (CRBU) has 7 years of Receivables data on file, last reported at $1.7 million in Q1 2026.

• On a quarterly basis, Receivables fell 13.46% year-over-year to $1.7 million in Q1 2026; TTM through Mar 2026 was $1.7 million, a 13.46% decrease from a year earlier, with the FY2025 full-year figure at $2.0 million, down 5.73% from the prior year.
• Receivables for Q1 2026 stood at $1.7 million, up from $145000.0 in the prior quarter.
• Over the last five years, Receivables for CRBU reached as high as $4.5 million in Q1 2022 and fell as low as -$283000.0 in Q4 2022.
• Historically, Receivables has averaged $2.0 million across 5 years, with a median of $2.0 million in 2025.
• Across the five-year window, Receivables slumped 122.11% in 2022 and surged 360.67% in 2024, its largest moves.
• Year by year, Receivables stood at -$283000.0 in 2022, then soared by 131.45% to $89000.0 in 2023, then jumped by 360.67% to $410000.0 in 2024, then tumbled by 64.63% to $145000.0 in 2025, then surged by 1053.1% to $1.7 million in 2026.
• Per Business Quant data, the three most recent Receivables figures were $1.7 million in Q1 2026, $145000.0 in Q4 2025, and $2.1 million in Q3 2025.